Literature DB >> 11316676

Meningococcal group C conjugate vaccines.

J Maclennan1.   

Abstract

Mesh:

Substances:

Year:  2001        PMID: 11316676      PMCID: PMC1718752          DOI: 10.1136/adc.84.5.383

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  47 in total

1.  Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.

Authors:  J M MacLennan; F Shackley; P T Heath; J J Deeks; C Flamank; M Herbert; H Griffiths; E Hatzmann; C Goilav; E R Moxon
Journal:  JAMA       Date:  2000-06-07       Impact factor: 56.272

2.  Changing epidemiology of meningococcal disease in Spain, 1989-1997.

Authors:  S Mateo; R Cano; C Garcia
Journal:  Euro Surveill       Date:  1997-10

3.  Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.

Authors:  P Richmond; D Goldblatt; P C Fusco; J D Fusco; I Heron; S Clark; R Borrow; F Michon
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

4.  Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3.

Authors:  J B Robbins; L Myerowitz; J K Whisnant; M Argaman; R Schneerson; Z T Handzel; E C Gotschlich
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

5.  The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis.

Authors:  C M Whalen; J C Hockin; A Ryan; F Ashton
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

Review 6.  Pneumococcal disease: prospects for a new generation of vaccines.

Authors:  G R Siber
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

7.  Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.

Authors:  R Borrow; P Richmond; E B Kaczmarski; A Iverson; S L Martin; J Findlow; M Acuna; E Longworth; R O'Connor; J Paul; E Miller
Journal:  FEMS Immunol Med Microbiol       Date:  2000-05

8.  A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants.

Authors:  P A Twumasi; S Kumah; A Leach; T J O'Dempsey; S J Ceesay; J Todd; C V Broome; G M Carlone; L B Pais; P K Holder
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

9.  Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.

Authors:  W J King; N E MacDonald; G Wells; J Huang; U Allen; F Chan; W Ferris; F Diaz-Mitoma; F Ashton
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

10.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

View more
  3 in total

1.  Meningococcal disease: oh no, not another childhood vaccine.

Authors:  Erica Weir
Journal:  CMAJ       Date:  2002-04-16       Impact factor: 8.262

Review 2.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

3.  The meningococcus tamed?

Authors:  A J Pollard; E R Moxon
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.